Immunosenescence and Cytomegalovirus: Exploring Their Connection in the Context of Aging, Health, and Disease

Int J Mol Sci. 2024 Jan 6;25(2):753. doi: 10.3390/ijms25020753.

Abstract

Aging induces numerous physiological alterations, with immunosenescence emerging as a pivotal factor. This phenomenon has attracted both researchers and clinicians, prompting profound questions about its implications for health and disease. Among the contributing factors, one intriguing actor in this complex interplay is human cytomegalovirus (CMV), a member of the herpesvirus family. Latent CMV infection exerts a profound influence on the aging immune system, potentially contributing to age-related diseases. This review delves into the intricate relationship between immunosenescence and CMV, revealing how chronic viral infection impacts the aging immune landscape. We explore the mechanisms through which CMV can impact both the composition and functionality of immune cell populations and induce shifts in inflammatory profiles with aging. Moreover, we examine the potential role of CMV in pathologies such as cardiovascular diseases, cancer, neurodegenerative disorders, COVID-19, and Long COVID. This review underlines the importance of understanding the complex interplay between immunosenescence and CMV. It offers insights into the pathophysiology of aging and age-associated diseases, as well as COVID-19 outcomes among the elderly. By unraveling the connections between immunosenescence and CMV, we gain a deeper understanding of aging's remarkable journey and the profound role that viral infections play in transforming the human immune system.

Keywords: CMV latency; COVID-19; SARS-CoV-2; age-related diseases; aging; cytomegalovirus; immunosenescence; inflammaging; long COVID.

Publication types

  • Review

MeSH terms

  • Aged
  • Aging
  • COVID-19*
  • Cytomegalovirus
  • Cytomegalovirus Infections*
  • Humans
  • Immunosenescence*
  • Latent Infection*
  • Post-Acute COVID-19 Syndrome

Grants and funding

This research received no external funding.